TY - JOUR
T1 - Analysis of human sperm karyotypes in testicular cancer patients before and after chemotherapy
AU - Martin, R. H.
AU - Ernst, S.
AU - Rademaker, A.
AU - Barclay, L.
AU - Ko, E.
AU - Summers, N.
PY - 1997/1/1
Y1 - 1997/1/1
N2 - Sperm karyotype analysis was performed on testicular cancer patients before and after treatment with BEP (bleomycin, etoposide, and cisplatin). A total of 788 sperm chromosome complements was studied, 236 before chemotherapy (CT) and 552 post-CT. There was no significant difference in the total frequency of sperm chromosomal abnormalities pre-CT (10.2%) compared to post-CT (10.7 %). Similarly, there were no significant differences in the frequencies of numerical abnormalities (2.5% pre-CT vs. 2.4% post-CT) or structural abnormalities (6.4% pre-CT vs. 7.4% post-CT). The percentage of X-bearing sperm was also not significantly different before (46.3%) and after CT (50.1%). The results in cancer patients were not significantly different from those in control donors. This study corroborates results from our previous analysis of these same men using multicolor fluorescence in situ hybridization for assessment of aneuploidy for chromosomes 1, 12, X, Y, and XY. Together, these two studies suggest that the sperm of men receiving BEP chemotherapy are not at increased risk of chromosomal abnormalities two or more years after treatment.
AB - Sperm karyotype analysis was performed on testicular cancer patients before and after treatment with BEP (bleomycin, etoposide, and cisplatin). A total of 788 sperm chromosome complements was studied, 236 before chemotherapy (CT) and 552 post-CT. There was no significant difference in the total frequency of sperm chromosomal abnormalities pre-CT (10.2%) compared to post-CT (10.7 %). Similarly, there were no significant differences in the frequencies of numerical abnormalities (2.5% pre-CT vs. 2.4% post-CT) or structural abnormalities (6.4% pre-CT vs. 7.4% post-CT). The percentage of X-bearing sperm was also not significantly different before (46.3%) and after CT (50.1%). The results in cancer patients were not significantly different from those in control donors. This study corroborates results from our previous analysis of these same men using multicolor fluorescence in situ hybridization for assessment of aneuploidy for chromosomes 1, 12, X, Y, and XY. Together, these two studies suggest that the sperm of men receiving BEP chemotherapy are not at increased risk of chromosomal abnormalities two or more years after treatment.
UR - http://www.scopus.com/inward/record.url?scp=0030700504&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0030700504&partnerID=8YFLogxK
U2 - 10.1159/000134642
DO - 10.1159/000134642
M3 - Article
C2 - 9371403
AN - SCOPUS:0030700504
SN - 0301-0171
VL - 78
SP - 120
EP - 123
JO - Cytogenetics and Cell Genetics
JF - Cytogenetics and Cell Genetics
IS - 2
ER -